SCR-M015
/ Simcere
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 18, 2026
SCR-M015, a PD-1/VEGF bispecific antibody exhibits potent anti-tumor efficacy in preclinical studies
(AACR 2026)
- "SCR-M015 inhibits PD-1/PD-L1 signaling and VEGF-A/VEGFR2 signaling in vitro and shows potent and superior anti-tumor activity in vivo. These preclinical data demonstrates the promising potential for further clinical investigation in various types of tumors."
Bispecific • Preclinical • Oncology • IFNG • IL2 • PD-1
1 to 1
Of
1
Go to page
1